1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Pipeline Update: New Antifungals Sprout In Warmer Regulatory Climate

 
• By Emily Hayes

Candidates from Cidara, Scynexis, Viamet and more featured in a symposium at the ICAAC/ICC meeting in September.

Under the sunlight of government incentives for development, the current crop of antifungal drugs is looking encouraging to infectious disease researchers, with improvements on old classes and a range of new targets emerging.

Antifungals make up the smallest part of the infectious disease market, behind antivirals (driven, of course, by new hepatitis C drugs), vaccines and antibacterial drugs. In fact, antifungals accounted for only $2

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.